QTI QT Imaging (QTI) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001844505
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter
QT Imaging insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for QT IMAGING HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.6% of the 1,168,035 shares held after it.
- 2 other insiders bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman Katz Avi S bought about $251.2K of QTI on Apr 9, 2025; 2 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.6% of the 1,168,035 shares held after it.
- 2 other insiders bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dinu Raluca bought about $251.2K of QTI on Apr 9, 2025; 2 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 12, 2024.
- 2 other insiders bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman GigAcquisitions5, LLC bought about $1.5M of QTI on Mar 21, 2025; 2 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 12, 2024.
- The trade is 15.2% of the 775,571 shares held after it.
- 2 other insiders bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman GigAcquisitions5, LLC bought about $68.2K of QTI on Mar 21, 2025; 2 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 68.2% of the 628,082 shares held after it.
- 4 other insiders bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GREENE JAMES S bought about $248.3K of QTI on Nov 12, 2024, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 76% of Medical Devices
Revenue
+287.9% year over year
more than 97% of Medical Devices
Margin
-111.4% net margin
below 80% of Medical Devices
Buybacks
no share repurchases reported
Short interest
1.7% of the float short (float per yahoo 2026-10-27) · 5.0 days to cover · settled 2026-10-15
below 69% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch QTI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-93.1%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns QTI: institutional holders (13F)
13F holdings, latest reported quarter
1,112,201 sh
$4.5M
702,776 sh
$2.9M
356,448 sh
$1.5M
316,667 sh
$1.3M
200,000 sh
$814.0K
Congress trades in QTI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
QTI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
QTI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$126.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$8.1K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$234.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$422.1K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$184.7K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$136.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
QTI financials
Revenue growth
+287.9%
XBRL, annual
Net margin
-111.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$26.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM QTI
| FY Dec 2025 | $18.9M |
| FY Dec 2024 | $4.9M |
| FY Dec 2023 | $40.4K |
| FY Dec 2022 | n/a |
| Jun 2026 | $7.4M |
| Mar 2026 | $6.5M |
| Dec 2025 | $8.3M |
| Sep 2025 | $4.2M |
| Jun 2025 | $3.7M |
| Mar 2025 | $2.8M |
| Dec 2024 | $846.8K |
| Sep 2024 | $956.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-77.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM QTI
| FY Dec 2025 | -111.4% |
| FY Dec 2024 | -184.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -148.9% |
| Mar 2026 | -52.2% |
| Dec 2025 | -16.8% |
| Sep 2025 | -108.7% |
| Jun 2025 | -109.4% |
| Mar 2025 | -397.9% |
| Dec 2024 | -411.9% |
| Sep 2024 | -378.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM QTI
| FY Dec 2025 | -$9.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -$5.0M |
| Mar 2026 | -$3.7M |
| Dec 2025 | -$3.2M |
| Sep 2025 | -$878.4K |
| Jun 2025 | -$1.5M |
| Mar 2025 | -$3.5M |
| Dec 2024 | -$1.3M |
| Sep 2024 | -$1.9M |
At each fiscal year end
Single quarter
Debt to equity
5.07x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity QTI
| FY Dec 2025 | 1.57x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 5.07x |
| Mar 2026 | 2.66x |
| Dec 2025 | 1.57x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.09x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt QTI
| FY Dec 2025 | -0.89x |
| FY Dec 2024 | -1.01x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -1.09x |
| Mar 2026 | -0.90x |
| Dec 2025 | -0.89x |
| Sep 2025 | -0.47x |
| Jun 2025 | -0.79x |
| Mar 2025 | -0.75x |
| Dec 2024 | -1.01x |
| Sep 2024 | -0.91x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2,125%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity QTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -2,125% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-96.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets QTI
| FY Dec 2025 | -144.9% |
| FY Dec 2024 | -140.5% |
| FY Dec 2023 | -25.1% |
| FY Dec 2022 | -2.0% |
| Jun 2026 | -96.6% |
| Mar 2026 | -81.2% |
| Dec 2025 | -144.9% |
| Sep 2025 | -243.0% |
| Jun 2025 | -198.5% |
| Mar 2025 | -164.3% |
| Dec 2024 | -140.5% |
| Sep 2024 | -46.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital QTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-49.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed QTI
| FY Dec 2025 | -77.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -27.0% |
| FY Dec 2022 | -3.2% |
| Jun 2026 | -49.6% |
| Mar 2026 | -60.2% |
| Dec 2025 | -77.5% |
| Sep 2025 | -1,280% |
| Jun 2025 | -1,543% |
| Mar 2025 | -108.6% |
| Dec 2024 | n/a |
| Sep 2024 | -139.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing QTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$34.1M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value QTI
| FY Dec 2025 | $72.3M |
| FY Dec 2024 | $168.5M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $49.5M |
| Mar 2026 | $73.9M |
| Dec 2025 | $72.3M |
| Sep 2025 | $1.0B |
| Jun 2025 | $576.7M |
| Mar 2025 | $257.9M |
| Dec 2024 | $168.5M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-37.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield QTI
| FY Dec 2025 | -12.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -26.0% |
| Mar 2026 | -13.0% |
| Dec 2025 | -12.5% |
| Sep 2025 | -0.7% |
| Jun 2025 | -1.4% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing QTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $18.9M | $4.9M | $40.4K | $0 |
| Gross profit | $8.6M | $2.6M | -$94.6K | n/a |
| Operating income | -$4.4M | -$12.2M | -$5.0M | -$4.3M |
| Net income | -$21.1M | -$9.0M | -$6.1M | -$2.8M |
| EPS (diluted) | -2.01 | -2.13 | -0.64 | -0.60 |
| Operating cash flow | -$9.0M | -$10.0M | -$2.7M | -$1.3M |
| Cash | $10.4M | $1.2M | n/a | n/a |
| Long-term debt | $10.1M | $9.9M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
QTI Stock Sonar score 5/7 axes
Find similar shapesCompareQTI ranks highest on growth (97th percentile) and risk and compliance (77th), and lowest on financial health (17th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
